Aurobindo joins growing list of drugmakers recalling ranitidine over cancer concerns

Aurobindo Pharma joined a growing list of drugmakers recalling their ranitidine products over concerns they produce a possible carcinogen.

Aurobindo is recalling one lot of its 150 mg ranitidine tablets to the retail level and 37 lots of its 150 mg and 300 mg ranitidine capsules and 15 mg/mL ranitidine syrup to the consumer level.

The drugmaker said it found N-nitrosodimethylamine in its ranitidine products, the same carcinogen found in several drugmakers' ranitidine products, which are used to treat heartburn.

Aurobindo said it has not received any reports of adverse events related to the recall and patients prescribed the ranitidine products should continue taking them but contact their pharmacist or physician to advise them about an alternative treatment.

Aurobindo's products were distributed nationwide between September 2018 and September 2019.

The latest recall comes as consumers have sued several drugmakers for allegedly failing to disclose the heartburn drug can produce small amounts of the possible carcinogen.

Read the full news release here.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars